Skip to main content
. Author manuscript; available in PMC: 2022 Dec 15.
Published in final edited form as: J Acquir Immune Defic Syndr. 2021 Dec 15;88(5):497–505. doi: 10.1097/QAI.0000000000002790

Table 1:

Baseline Characteristics by Site-Level

Outcome COMB-R
(N=6)
ESC
(N=7)
 P-value

Mean (s.d.) Mean (s.d.)
% Male 44.9 (24.4) 44.6 (24.5) 0.98
Mean age (yrs) at entry 21.5 (0.6) 21.3 (1.8) 0.74
% Younger (12-18 yrs) 17.1 (11.0) 25.8 (28.3) 0.50
% Black 65.1 (40.0) 57.0 (32.6) 0.69
% with perinatal transmission 49.1 (26.3) 56.2 (22.1) 0.61
Mean QIDS-C 16.6 (1.4) 15.1 (2.0) 0.15
Mean ordinal QIDS-C 3.7 (0.4) 3.5 (0.3) 0.25
% with severe QIDS-C 53.8 (21.9) 42.6 (32.3) 0.49
Mean QIDS-SR 16.2 (1.3) 14.5 (3.2) 0.26
Mean ordinal QIDS-SR 3.6 (0.3) 3.3 (0.8) 0.35
% with severe QIDS-SR 55.2 (16.5) 39.3 (32.0) 0.30
Mean log10 RNA/ml 2.2 (0.7) 2.1 (0.3) 0.82
% with viral suppression (< 40 copies/ml) 59.1 (27.3) 56.2 (10.0) 0.81
Mean CD4 count/uL 679.2 (150.7) 704.7 (203.8) 0.81
% with stage 3 CD4 count (<200 cells/uL) 9.8 (11.4) 7.9 (9.9) 0.76
% with stage 3 nadir CD4 count 28.3 (23.1) 25.7 (21.1) 0.83
% with stage 3 CDC class 20.3 (29.1) 22.0 (21.5) 0.91
% on ARVs 93.2 (6.7) 92.0 (18.7) 0.88
% on integrase inhibitors 73.8 (15.7) 66.6 (32.1) 0.63
% on psychiatric medications 28.0 (13.2) 21.4 (19.0) 0.49
% on 2 or more psychiatric medications 30.0 (20.0) 44.8 (42.2) 0.45
% on anti-depressant medications 25.2 (9.8) 21.4 (19.0) 0.67
% on SSRI anti-depressant medications 20.3 (10.5) 15.8 (16.8) 0.58

Note:

*

indicates p-value < 0.05, t-test with equal or unequal variances as appropriate based on F-test results

Note: For analysis of dichotomous variables, entries are means (s.d.) of site-specific percentages

Note: Quick Inventory for Depression Symptomatology Clinician Report (QIDS-C) and Self-Report (QIDS-SR) is scored from 0-27 with a higher score indicating greater symptom severity: 0-5 Not depressed, 6-10 Mild, 11-15 Moderate. 16-20 Severe, 21+ Very Severe

Note: Mean ordinal QIDS-C and QIDS-SR measures are ranked from 1-5 (none to very severe) and analyzed as a continuous measure

Note: Stage 3 nadir CD4 is computed across age ranges where Stage 3 was <750 cells (at < 1 year old), <500 cells at 1-5 yrs and < 200 cells at 6+ years

Note: Denominator for percent of participants on 2 or more psychiatric medications is the number on any psychiatric medication

Note: Denominator for percent of participants on INSTIs is the number on any ARV